Labatec Pharma announces exclusive licensing agreement signed with Radius Health Inc., to commercialise Tymlos in Switzerland and the Middle East North Africa region
14 juin 2022
LABATEC PHARMA ANNOUNCES EXCLUSIVE LICENSING AGREEMENT SIGNED WITH RADIUS HEALTH INC, TO COMMERCIALISE TYMLOS IN SWITZERLAND AND THE MIDDLE EAST NORTH AFRICA REGION Geneva, June 9, 2022 – Labatec Pharma SA (Labatec) signed a new licensing agreement with Radius Health, Inc. (Radius) (NASDAQ: RDUS), for the rights to commercialise TYMLOS® (abaloparatide), a subcutaneous injection […]